ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

This study is testing a drug called ProAgio in patients with advanced pancreatic cancer (pancreatic ductal adenocarcinoma, stage IV — meaning the cancer has spread to other organs). ProAgio targets a specific protein in the tumor's blood vessel environment to cut off the tumor's blood supply, potentially making it easier for chemotherapy to work. **You may be eligible if...** - You are 18 or older with a confirmed stage IV pancreatic cancer diagnosis - You are eligible for standard chemotherapy (gemcitabine + nab-paclitaxel) for the dose escalation phase, OR - You have already received 5-FU-based chemotherapy for your pancreatic cancer in the expansion phase **You may NOT be eligible if...** - Your pancreatic cancer is at an earlier stage or is a different type - You have serious organ problems or have had certain prior treatments - You are pregnant or breastfeeding - You are unable to tolerate chemotherapy Talk to your doctor to see if this trial is right for you.